Aphios Corporation Receives Patent Allowance for Innovative Bryoid Composition Platform Aimed at Alzheimer’s, Multiple Sclerosis, HIV Reservoirs, and Oncology Applications
Aphios Corporation has announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a divisional patent application covering novel Bryoid compounds with potential applications across several major disease areas, including neurodegenerative disorders, HIV latency, cancer, and amyloid-associated diseases. The patent application, titled “Bryoid Compositions, Methods of Making and Use Thereof,” represents another expansion of the company’s growing intellectual property portfolio focused on marine-derived therapeutics and advanced purification technologies.
According to the company, the newly allowed claims relate specifically to a proprietary Bryoid composition identified as B14B, as well as methods involving its isolation, purification, and manufacturing processes. The USPTO determined that the claimed composition demonstrated both novelty and non-obviousness compared with previously known bryostatin-related compounds, an important requirement for patent approval in the United States.
The announcement marks a significant milestone for Aphios as it continues developing its Bryoid platform, which is built around compounds derived from marine bryozoan natural products. These marine organisms have long attracted scientific interest because of their ability to produce complex bioactive molecules with potential pharmaceutical applications.
The company stated that the invention underlying the patent application was developed with support from the National Institute on Aging and the National Institutes of Health, highlighting the broader scientific and public health interest in novel approaches targeting neurodegenerative disease and other difficult-to-treat conditions.
Bryoids are structurally related to bryostatins, a class of naturally occurring macrocyclic lactones that have been studied for decades because of their ability to regulate protein kinase C (PKC) signaling pathways. PKC pathways are involved in numerous cellular functions, including memory formation, immune regulation, inflammation, cell growth, and apoptosis.
Because of their biological activity, bryostatin compounds have attracted substantial interest as potential therapeutics in areas such as Alzheimer’s Disease, Parkinson’s Disease, HIV latency reversal, multiple sclerosis, and oncology. However, limitations related to supply, purification complexity, and manufacturing scalability have historically challenged broader development efforts involving bryostatin-based therapeutics.
Aphios believes its Bryoid platform may help overcome some of these barriers by enabling the discovery and purification of structurally distinct compounds with potentially enhanced biological activity and improved manufacturing characteristics.
According to the patent specification referenced in the announcement, several of the company’s novel Bryoid compositions demonstrated biological activity equal to or greater than Bryostatin-1 in stimulating alpha-secretase activity and modulating PKC signaling pathways associated with neurodegenerative disorders and central nervous system diseases.
Alpha-secretase activation has become an important area of research in Alzheimer’s disease because of its role in processing amyloid precursor protein through non-amyloidogenic pathways. Increased alpha-secretase activity may help reduce the formation of beta-amyloid plaques, which are widely associated with the progression of Alzheimer’s disease and other amyloid-related disorders.
The company noted that experimental data described in the patent application showed enhanced alpha-secretase activity and PKC modulation in SHSY-5Y neuroblastoma cells, a commonly used cellular model in neurological and neurodegenerative disease research. These findings suggest that certain Bryoid compounds may possess therapeutic properties relevant to disorders involving amyloid accumulation and neuronal dysfunction.
The patent application also describes multiple proprietary Bryoid analogs with molecular weights distinct from known Bryostatin compounds numbered 1 through 20. Structural differentiation is particularly important in intellectual property development because it supports claims of novelty while potentially enabling distinct pharmacological profiles and therapeutic advantages.
Dr. Trevor P. Castor, Founder and Chief Executive Officer of Aphios Corporation, described the Bryoid platform as a significant advancement in the discovery and development of marine-derived therapeutics. He stated that the USPTO’s Notice of Allowance further validates the novelty of the company’s technology and strengthens its intellectual property estate across several therapeutic categories.
Castor emphasized the broad potential applications of the technology, including treatments for neurodegenerative diseases, HIV latency reversal strategies, and oncology indications. According to the company, these disease areas represent major unmet medical needs where innovative mechanisms of action could provide important clinical benefits.
One of the notable aspects of the Aphios platform is its use of proprietary extraction and purification technologies designed to isolate highly purified Bryoid compounds from marine sources such as Bugula neritina, a bryozoan species known for producing bryostatin-related molecules.
The company combines these extraction methods with its SuperFluids™ processing platform, which is intended to improve compound purification efficiency and scalability. Advanced purification methods are especially important in marine natural product research because many bioactive compounds occur only in extremely small quantities in nature, making traditional extraction and manufacturing difficult.
Marine natural products have long been viewed as a promising but technically challenging source of drug candidates. Oceans contain immense biological diversity, and marine organisms often produce chemically unique compounds not found in terrestrial ecosystems. However, commercialization of marine-derived therapeutics has historically been limited by challenges related to sourcing, reproducibility, scalability, and purification.
Aphios’ approach seeks to address these limitations by integrating natural product discovery with proprietary processing and manufacturing technologies. The company believes this combination may support development of next-generation therapeutics with applications in diseases characterized by neurological degeneration, immune dysfunction, viral persistence, and abnormal cellular growth.
Among the disease areas highlighted by Aphios are Multiple Sclerosis and HIV-1 latency. HIV latency reversal remains an important area of biomedical research because latent viral reservoirs represent one of the primary obstacles preventing a cure for HIV infection. PKC activators such as bryostatin analogs have been investigated for their ability to reactivate latent HIV, potentially enabling eradication strategies when combined with antiretroviral therapy.
Similarly, PKC modulation has attracted attention in oncology because these signaling pathways play central roles in tumor growth, immune activation, apoptosis, and cancer cell survival. Compounds capable of selectively influencing these pathways may eventually support development of novel cancer therapies or combination treatment approaches.
Neurodegenerative diseases remain another major focus area for bryostatin-related research. Conditions such as Alzheimer’s disease and Parkinson’s disease continue to impose substantial medical, social, and economic burdens globally, while effective disease-modifying therapies remain limited.
Researchers have increasingly explored mechanisms capable of enhancing synaptic function, reducing amyloid accumulation, promoting neuronal survival, and modulating neuroinflammation. PKC-targeting compounds have emerged as one possible approach because of their involvement in neuronal signaling and synaptic plasticity.
Aphios stated that its growing Bryoid intellectual property portfolio now includes more than 85 issued and pending United States and international patents. The latest Notice of Allowance expands this portfolio and may strengthen the company’s strategic position in the competitive field of marine-derived therapeutic development.
The announcement also reflects broader trends within biotechnology and pharmaceutical research toward exploring naturally derived compounds as sources of innovative therapeutics. Advances in analytical chemistry, molecular biology, and purification technologies have renewed interest in complex natural products that were previously difficult to isolate or manufacture efficiently.
While many marine-derived compounds remain in early-stage research and development, several have already reached clinical use in oncology and other therapeutic areas, demonstrating the pharmaceutical potential of ocean-derived bioactive molecules.
Aphios appears focused on leveraging this scientific momentum through its integrated platform approach, which combines marine natural product sourcing, proprietary extraction technologies, purification methods, and intellectual property development.
The company’s continued emphasis on building a broad patent estate may also support future licensing, partnership, and commercialization opportunities as interest in PKC-modulating therapies and neurodegenerative disease treatments continues to grow.
Although the announcement primarily concerns intellectual property advancement rather than clinical-stage data, the Notice of Allowance provides additional validation of the uniqueness of Aphios’ Bryoid compositions and processing technologies. Securing patent protection remains a critical component of biotechnology development, particularly for companies working in highly specialized and competitive therapeutic areas.
As research into PKC modulation, amyloid biology, and marine-derived therapeutics continues to evolve, Aphios aims to position its Bryoid platform as a potential source of next-generation treatments targeting some of the most challenging diseases in medicine, including neurodegenerative disorders, cancer, and chronic viral infections.
About Aphios Corporation
Aphios Corporation is an emerging growth biotechnology company developing enhanced therapeutics and enabling technologies for drug discovery, drug delivery, and pathogen safety. The company’s proprietary platforms include SuperFluids™ extraction and purification, nanotechnology-based drug delivery systems, and novel therapeutics targeting cancer, infectious diseases, and CNS disorders including Alzheimer’s disease, addiction, pain, and anxiety.
This research was in part funded by an SBIR Grant from the National Institute on Aging (NIA), NIH. The content of this release is solely the responsibility of the authors and does not represent the official views of NIA and NIH.
